Loading company…
SmartZyme BioPharma develops glycan-based therapeutics and bioconjugation technologies for glycobiology.
Founded in 2013 and headquartered in New York, US, SmartZyme BioPharma, Inc. works on glycan-based therapeutics and bioconjugation technologies for cancer diagnostics and vaccine development. Its assay kits, enzymes and recombinant proteins serve research institutions, pharmaceutical companies and biotechnology firms in North America, Europe and Asia. On March 14, 2018 it raised USD 4.00 mn, led by OrbiMed Advisors, as the first tranche of Series B financing, and the company has completed two deals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in